Wednesday, June 14, 2006 :: CT Laser Mammography Clinical Results to be Featured at Milan Breast Cancer Conference
CT Laser Mammography Clinical Results to be Featured at Milan Breast Cancer Conference


Fort Lauderdale, Florida, June 14, 2006—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced that CT Laser Mammography (CTLM®) clinical results will be featured at the 8th Milan Breast Cancer Conference, June 21-23, in Milan, Italy.

This year’s meeting, “Innovation in Care and Research,” is dedicated to breast cancer prevention, detection and treatment developments. The conference will highlight the tailoring of therapeutic approaches to the needs of the individual patient.

The Milan Breast Cancer Conference is organized by the prestigious European Institute of Oncology (EIO), a comprehensive cancer center that provides diagnostic services and treatment, conducts research, and participates in clinical trials. The EIO is also one of IDSI’s clinical collaboration sites.

Italy has been an early adopter of CTLM technology in both research and clinical settings. IDSI has four installations in the country.

The CTLM results will be located at booth 7. For more information on the 8th Milan Breast Cancer Conference, visit the conference website: http://www.breastmilan.com/index.php.
As previously stated the company’s CTLM system has recently entered US clinical trials for submission of the PMA application.

Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. The CTLM system is limited by United States Federal Law to investigational use only in the United States. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Tuesday, June 13, 2006 :: Third CT Laser Mammography System Sold In Poland
Third CT Laser Mammography System Sold In Poland


Fort Lauderdale, Florida, June 13, 2006—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today the sale and shipment of a third CT Laser Mammography (CTLM®) system to IDSI’s exclusive distributor in Poland, EDO MED Sp. z.o.o. The CTLM system is to be installed at the Regional Center of Oncology, Bydgoszcz, Poland.

The installation will mark the third CTLM system to enter Poland’s Institute of Oncology system. Poland has embarked on a 10-year National Cancer Program initiative and has been an early adopter of CT laser breast imaging technology in both research and clinical settings.

The Regional Center conducts research activities in cooperation with leading oncology centers and medical academies and organizes scientific conferences at home and abroad. It has been registered by the European and World Network of Hospitals for Health Promotion and by the Organization of European Cancer Institutes (OECI). In October 2004, the Center was granted the title of "Best Public Hospital in Poland."

“We are pleased that another CTLM system is slated to be installed in Poland’s leading oncology system,” stated Tim Hansen, IDSI Chief Executive Officer. “Through this installation, we will increase accessibility of the new laser breast imaging technology to women in Poland.”

Information on the Regional Center of Oncology can be obtained from their website: http://www.co.bydgoszcz.pl/en/

Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The Company's PMA application will be submitted in its entirety at the completion of the data collection and review process. The FDA has determined that the Company’s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. The CTLM system is an investigational device and is not available in the United States. It is limited by United States Federal Law to investigational use. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
404-261-1196

Monday, May 1, 2006 :: Imaging Diagnostic Systems’ CT Laser Breast Imaging Scanner
Imaging Diagnostic Systems’ CT Laser Breast Imaging Scanner
Enters US FDA Clinical Trials


Fort Lauderdale, Florida, May 1, 2006—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that clinical trials of the CT Laser Mammography (CTLM®) system have commenced at a number of US university medical centers. IDSI will collect clinical data through a non-significant risk (NSR) device study.

“As previously reported, we will be scanning patients using the latest version of the CTLM system,” commented Deborah O’Brien, Senior Vice President of Imaging Diagnostic Systems. “Following data collection and analysis, we intend to submit a Premarket Approval application to the FDA for the use of CTLM as an imaging adjunct to conventional diagnostic mammography. CTLM has the potential to fill an important role in improving the accuracy of current breast cancer detection methods and in improving patient management. We are partnering with prestigious institutions, using an experienced clinical study management firm, working with leading regulatory consultants, and using our best efforts to ensure successful clinical trials.”

“We are also moving forward in our global commercialization efforts. We held our first International CTLM Users Meeting in April. Many of our international users have gained useful experience and collectively have scanned over 7,000 breasts. IDSI recently participated in the European Congress of Radiology, where several of our luminary partners presented clinical studies,” O’Brien added.

The Company will continue to provide periodic updates of its progress on current initiatives, including the US PMA process, by way of shareholder letters, press releases, and other public filings. The locations of the clinical trials will not be disclosed so that the study members may participate without publicity or distraction.

Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The Company's PMA application will be submitted in its entirety at the completion of the data collection and review process. The FDA has determined that the Company’s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Tuesday, April 25, 2006 :: Imaging Diagnostic Systems Holds 1st International CT Laser Mammography Users Meeting in Berlin
Imaging Diagnostic Systems Holds 1st International CT Laser Mammography Users Meeting in Berlin


Fort Lauderdale, Florida, April 25, 2006—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) held the 1st International CTLM Users Meeting, a forum for physicians throughout the world who work with the CT Laser Mammography system. Hosted by Alexander Poellinger, MD, a principal CTLM investigator at Charité Hospital in Berlin, Germany, the April 22 – 23 meeting allowed users to share their clinical and scientific experiences with the innovative CTLM® technology, to discuss patient study results, and to exchange ideas for future radiologic and oncologic applications of this exciting new technology.

Professor Bernd Hamm, Director of the Department of Radiology at the Charité Hospital, stated, “Our department offers a wide variety of state-of-the-art diagnostic procedures, including digital mammography, sonography, breast MRI, and vacuum-assisted breast biopsy. As one of the largest university hospitals worldwide, we have been working on different innovative imaging technologies including impedance scanning, contrast-enhanced digital mammography and laser optical mammography. CTLM, as a new diagnostic tool, yields the possibility of being added to this multidisciplinary approach. We are very proud to have hosted the first CTLM users’ meeting in Berlin.”

Physicians at the 1st International Meeting represented some of the world’s leading research hospitals, including Charité Hospital, Berlin, Germany; Catholic University, Rome, Italy; Gazi University, Ankara, Turkey; Charles University, Prague, Czech Republic; Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland; and the Medical University of Vienna, Vienna, Austria. Works from other sites were also presented.

“We have developed a large body of work, which made it imperative to convene our 1st International CTLM Users Meeting. The meeting allowed us to gather and document significant clinical observations and data developed by the CTLM user physicians. These physicians have been routinely providing us with valuable information; it was important to have them share experiences with peers because this technology is so new and unique. We appreciate the input from such experienced users of the CTLM system, who together have performed over 7000 clinical scans,” stated Deborah O’Brien, Senior Vice President, Imaging Diagnostic Systems.

Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Mammography (CTLM®) system to be used as an adjunct to mammography. The Company's PMA application will be submitted in its entirety at the completion of the data collection and review process. The FDA has determined that the Company’s clinical investigation is a non-significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. IDSI has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Mammography system.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com